Extracorporeal carbon dioxide removal

ALung Announces a Key Milestone Achievement in its VENT-AVOID Pivotal Trial

Retrieved on: 
Tuesday, March 16, 2021
Nursing, Medical Supplies, Finance, Surgery, Health, Medical devices, Hospitals, Professional services, Medical specialties, Clinical medicine, Health, Intensive care medicine, Chronic lower respiratory diseases, Respiratory therapy, Chronic obstructive pulmonary disease, Extracorporeal carbon dioxide removal, Mechanical ventilation, Respiratory disease

ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent achievement of a significant milestone - enrollment of 100 patients in its U.S. based VENT-AVOID pivotal trial.

Key Points: 
  • ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent achievement of a significant milestone - enrollment of 100 patients in its U.S. based VENT-AVOID pivotal trial.
  • VENT-AVOID is a randomized, controlled pivotal trial (RCT) studying the avoidance or minimization of mechanical ventilation for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AE-COPD).
  • The VENT-AVOID pivotal trial is currently the worlds largest trial ever conducted on the utilization of ECCO2R in AE-COPD with 100 patients now enrolled.
  • Subsequent to receiving Emergency Use Authorization (EUA) from the FDA, ALung has provided ECCO2R therapy to 93 COVID-19 patients worldwide.

ALung Announces Continued Progress Towards Completion of Two Landmark Pivotal Trials

Retrieved on: 
Tuesday, December 3, 2019
Research, General Health, Medical devices, Hospitals, Clinical trials, Science, Surgery, Biotechnology, Nursing, Medical Supplies, FDA, Health, Medical specialties, Medicine, Health, Intensive care medicine, Chronic lower respiratory diseases, Respiratory therapy, Respiratory diseases, Mechanical ventilation, Chronic obstructive pulmonary disease, Extracorporeal carbon dioxide removal, COPD: Journal of Chronic Obstructive Pulmonary Disease, Respiratory disease

The VENT-AVOID pivotal trial is studying the avoidance or minimization of the need for mechanical ventilation in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AE-COPD).

Key Points: 
  • The VENT-AVOID pivotal trial is studying the avoidance or minimization of the need for mechanical ventilation in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AE-COPD).
  • The VENT-AVOID pivotal trial is now the worlds largest prospective Randomized Controlled Trial (RCT) ever conducted on the utilization of ECCO2R in AE-COPD with greater than 60 patients now enrolled.
  • ALung is the only company pursuing two major pivotal trials to validate the safety and efficacy of extracorporeal carbon dioxide removal therapy.
  • ALung Technologies, Inc. is a privately held Pittsburgh-based developer and manufacturer of innovative lung assist devices.